On 14 December 2005, orphan designation (EU/3/05/332) was granted by the European Commission to Vion (UK) Limited, United Kingdom, for 1,2-bi (methylsulphonyl)-1-(2-chloroethyl)-2- [(methylamino)carbonyl]hydrazine for the treatment of acute myeloid leukaemia.
Treatment of acute myeloid leukaemia
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
EU/3/05/332: Public summary of positive opinion for orphan designation of 1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine for the treatment acute myeloid leukaemia (PDF/173.72 KB)
First published: 09/02/2006
Last updated: 09/02/2006
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: